Biodexa Pharmaceuticals Plc ADR(BDRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 22 at 5:30 AM ET (Korea 10/22 18:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -6.7 | Insider Own | - | Shs Outstand | 7.46B | Perf Week | -13.4% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | -38.34% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | 0 | Inst Own | 1.49% | Short Float | - | Perf Quarter | -75.01% |
| Income | -0.01B | P/S | - | EPS this Y | 100% | Inst Trans | -6.9% | Short Ratio | 0 | Perf Half Y | -89.21% |
| Sales | 0.00B | P/B | 2624.38 | EPS next 5Y | - | ROA | -31.88% | Short Interest | 0.02M | Perf YTD | -96.3% |
| Book/sh | 0 | P/C | 0.1 | EPS past 3/5Y | 95.64% 89.65% | ROE | -41.72% | 52W High | -99.06% ($44.70) | Perf Year | -98.89% |
| Cash/sh | 4.17 | P/FCF | - | Sales past 3/5Y | - | ROIC | -46.48% | 52W Low | 24.56% ($0.34) | Perf 3Y | -99.99% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 97.97% | Gross Margin | - | Volatility(W/M) | 13.74% 12.19% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.1 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 2.41 | EPS Q/Q | 100% | Profit Margin | - | RSI (14) | 36.71 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.41 | Sales Q/Q | - | SMA20 | -21.09% ($0.53) | Beta | 1.24 | Target Price | $9 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/9/11 | SMA50 | -49.49% ($0.83) | Rel Volume | 0.05 | Prev Close | $0.39 |
| Employees | 11 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -88.21% ($3.56) | Avg Volume(3M) | 4.91M | Price | $0.42 |
| IPO | 2015/12/7 | Option/Short | No/Yes | Trades | 549 | Volume | 253,392 | Change | 8.91% |
💊 Clinical-stage biotech. eRapa FAP therapeutic. Phase 3 Serenta clinical trial. Government grant funding. UK-based. Unmet medical need.
Over the past 1 year, on the lower side
99% below its 1-year high.
Traded less than usual. That is 5% of its average volume.
BDRX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +100.0% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.5%.
Tap to view numbers
It ranks #593 of 595 in the industry
Based on market cap of $0M.
LABT#590 Lakewood-Amedex Biotherapeutics Inc $1M PER - 
CRIS#591 Curis Inc $1M PER - 
SPRC#592 SciSparc Ltd $1M PER - BDRX#593 Biodexa Pharmaceuticals Plc ADR $0M PER - 
SCNI#593 Scinai Immunotherapeutics Ltd ADR $0M PER - 
FAQ
What kind of company is BDRX?
BDRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BDRX?
The market cap of BDRX is approximately $0M, ranking 5,884 within its sector.
What is the 52-week high and low for BDRX?
BDRX has recorded a 52-week high of $44.70 and a low of $0.34.
